Post date March 29, 2024 Experience AnHeart Therapeutics acquisition by Nuvation Bio We are advising AnHeart Therapeutics on the acquisition
Post date February 12, 2024 Experience Gilead Sciences $4.3 billion acquisition of CymaBay Therapeutics We are advising Gilead Sciences on the acquisition
Post date February 5, 2024 Experience Novo Nordisk acquisition of certain Catalent sites from Novo Holdings We are advising Novo Nordisk on the acquisition
Post date January 11, 2024 Experience Roche $295 million acquisition of LumiraDx's point of care technology platform We are advising Roche on the acquisition
Post date December 21, 2023 Experience GSK exclusive license agreement for HS-20093 with Hansoh Pharma We advised GSK on the transaction
Post date November 22, 2023 Experience Smith+Nephew acquisition of CartiHeal We are advising Smith+Nephew on the acquisition
Post date November 1, 2023 Experience Forbion European Acquisition $138 million combination with enGene We advised Forbion European Acquisition on its de-SPAC transaction
Post date October 31, 2023 Experience GSK exclusive license agreement for HS-20089 with Hansoh Pharma We advised GSK on the transaction
Post date October 30, 2023 Experience GSK collaboration extension and new data licensing agreement with 23andMe We advised GSK on the transaction
Post date October 23, 2023 Experience Roche $7.1 billion acquisition of Telavant and rights to RVT 3101 from Roivant We are advising Roche on the acquisition